Grifols

Grifols, S.A.
Company type	Public
Traded as	BMAD: GRF; Nasdaq: GRFS;
ISIN	ES0171996012
Industry	Pharmaceuticals, chemicals
Founded	1940
Headquarters	Barcelona, Spain
Key people	Nacho Abia (CEO); Thomas Glanzmann (chairman);
Products	Plasma derivatives, in vitro diagnostic products, non-biological products for laboratories and hospitals
Revenue	€6.064 billion (2022)
Operating income	€805.7 million (2022)
Net income	€271.1 million (2022)
Total assets	€21.53 billion (2022)
Total equity	€8.457 billion (2022)
Number of employees	26,314 (2022)
Website	grifols.com
	Footnotes / references;

Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma–based products, a field in which it is the European leader and largest worldwide,^[3]^[4] the company also supplies devices, instruments, and reagents for clinical testing laboratories.

^ "2022 Annual Report (Form 20-F)". US Securities and Exchange Commission. Retrieved 2023-04-18.
^ "Grifols appoints new CEO Nacho Abia to the board". Nasdaq. Retrieved 2024-04-03.
^ Smyth, Sharon; Gore, Gareth (23 June 2008). "Santander, Sabadell, Sol Melia, Urbas: Iberia Preview". Bloomberg. Archived from the original on 23 October 2012. Retrieved 2009-01-18.
^ "Novartis Sells Blood Transfusion Dx Unit to Grifols". Genetic Engineering & Biotechnology News (Paper). Vol. 33, no. 21. December 2013. p. 10.